These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 16224275

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ, Malya R, Rawat A.
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [Abstract] [Full Text] [Related]

  • 4. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis.
    Hotton KM, Khorsand M, Hank JA, Albertini M, Kim KM, Wilding G, Salamat MS, Larson M, Sondel P, Schiller JH.
    Cancer; 2000 Apr 15; 88(8):1892-901. PubMed ID: 10760767
    [Abstract] [Full Text] [Related]

  • 5. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI.
    BJU Int; 2012 Jan 15; 109(1):63-9. PubMed ID: 21244601
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
    Westermann J, Reich G, Kopp J, Haus U, Dörken B, Pezzutto A.
    Cancer Immunol Immunother; 2001 Jan 15; 49(11):613-20. PubMed ID: 11225992
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
    Lissoni P, Mengo S, Bucovec R, Brivio F, Fumagalli L, Tancini G, Gardani GS.
    In Vivo; 2003 Jan 15; 17(1):73-5. PubMed ID: 12655794
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC.
    Br J Cancer; 2003 May 06; 88(9):1346-51. PubMed ID: 12778059
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma.
    Witte RS, Leong T, Ernstoff MS, Krigel RL, Oken MM, Harris J, Tormey DC, Trump DL.
    Invest New Drugs; 1995 May 06; 13(3):241-7. PubMed ID: 8729953
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
    Huland E, Heinzer H, Huland H.
    J Cancer Res Clin Oncol; 1994 May 06; 120(4):221-8. PubMed ID: 8288676
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects.
    Tate J, Olencki T, Finke J, Kottke-Marchant K, Rybicki LA, Bukowski RM.
    Ann Oncol; 2001 May 06; 12(5):655-9. PubMed ID: 11432624
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
    Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R.
    Cancer Invest; 2005 May 06; 23(4):303-8. PubMed ID: 16100942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.